-
Tracheostomy confers patient benefits such as decreasing laryngeal irritation, improving patient communication, and decreasing sedation requirements, but the optimal timing of this procedure in critically ill patients remains a subject of considerable debate.
-
-
With HIV/AIDS medical providers and AIDS service organizations (ASOs) all making do with less federal money these days, there is a new model for how the two groups can help more HIV patients with medical treatment adherence through collaboration.
-
Is rapid HIV testing in use in your local family planning facility? Findings from a 2007 survey conducted by the National Alliance of State and Territorial AIDS Directors Rapid point to "yes"; 94% of health departments indicated they use rapid HIV testing as part of health department-supported HIV testing programs.1
-
-
Next month a new administration will usher in great expectations with regard to how President-elect Barack Obama will fund a variety of domestic programs, including HIV/AIDS prevention and medical care.
-
A New York City AIDS organization has demonstrated for years how to stretch funding and make programs more effective through a combination of collaborative meetings, networking, and volunteers.
-
Review the last three patient charts: a 19-year-old college student, a 26-year-old mother of two, and a 43-year-old woman who is newly divorced. Which women were offered screening for HIV?
-
FDA approves generic lamivudine: On Oct. 7, 2008, the FDA granted tentative approval for a generic formulation of lamivudine 150 mg and 300 mg tablets, manufactured by Macleods Pharmaceuticals Limited of Daman, India, indicated for use in combination with other anti-retroviral drugs for the treatment of HIV-1 infection.
-
Among almost 6000 patients with COPD who were using other classes of respiratory therapies, the addition of tiotropium, compared with placebo, was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period, but did not result in benefits in the rate of decline in FEV1.
